Profusa's Landmark Study on Lumee Oxygen Monitoring
Data from a crucial clinical study indicates that the Lumee™ Oxygen tissue monitoring system is proving to be an effective tool for long-term management of patients with peripheral artery disease (PAD). Profusa, Inc., a trailblazer in digital health, presented interesting findings during the late-breaking clinical trials at the Paris Vascular Insights in France. The findings confirm the successful achievement of primary end points as guided by the FDA.
Promising Results from the Clinical Trial
During the recently concluded conference, Profusa illustrated how the data gathered from their clinical study signifies that Lumee is not only a safe option for monitoring PAD but also correlates reliably with traditional methods of measuring tissue oxygen levels. The study was conducted at various notable medical institutions, including the University of California San Francisco and the San Francisco VA Medical Center.
Key Highlights of the Study
The study focused on 15 PAD patients equipped with Lumee's innovative hydrogel sensors, implanted in both arms and feet. Participants were observed over a year, with check-ins on various days to ensure comprehensive monitoring of their condition. Here are some significant findings from the pilot phase:
Effective Correlation with Standard Measures
The Lumee monitoring system showed a robust correlation with traditional transcutaneous partial pressure of oxygen (tcpO?). Both devices used in the study detected drops in oxygen levels during vascular occlusion, indicating the potential of Lumee as a reliable monitoring tool.
Sensor Longevity and Safety
Remarkably, the Lumee sensors maintained functionality throughout the study, remaining operational for as long as a year. Importantly, there were no reported adverse events connected to sensor placement, which underscores the safety of this advanced monitoring system.
Future Steps and Market Potential
Ben Hwang, Ph.D., Chairman and CEO of Profusa, expressed confidence in the results and their implication for patient treatment. He stated, "Our Lumee oxygen monitoring technology is designed for seamless use in both clinical settings and at home. The presented data is instrumental for our upcoming FDA submission aimed at enhancing accessibility for patients. We anticipate that the commercialization of Lumee will commence in the European Union in the early part of 2026. With over 716,000 critical limb ischemia procedures anticipated annually in Europe, we are eager to cater to this urgent healthcare need."
About Profusa, Inc.
Based in Berkeley, California, Profusa is a pioneering company in the digital health landscape. Led by visionary founders and a seasoned management team, Profusa is committed to developing tissue-integrated sensors that can provide continuous, actionable medical data. Their innovative approach delivers reliable biosensors designed for affordability and accessibility, aiming to empower both individuals and healthcare providers in managing health more effectively.
Frequently Asked Questions
What is the Lumee monitoring system?
The Lumee monitoring system is a tissue oxygen monitoring technology designed to provide continuous and accurate oxygen level readings for patients with peripheral artery disease.
How effective is the Lumee technology in clinical settings?
Clinical data indicates that Lumee demonstrates strong correlations with traditional oxygen monitoring methods, showing its reliability and effectiveness for long-term use.
What are the safety details regarding the Lumee sensors?
The Lumee sensors have shown no adverse events related to their placement, indicating a high level of safety for patients using this technology.
What are Profusa's plans for the future?
Profusa plans to submit their findings to the FDA and aims to start commercializing the Lumee monitoring system in the European Union in early 2026.
How does Profusa address the needs of patients?
Profusa focuses on providing efficient and effective monitoring solutions that can empower patients in managing their health, particularly those with chronic conditions such as PAD.
